24-hour Efficacy and Ocular Surface Health With PF Tafluprost and Combined Therapy With PF Tafluprost and Dorzolamide/Timolol Fixed Combination in Open-angle Glaucoma Subjects Insufficiently Controlled With Latanoprost

Trial Profile

24-hour Efficacy and Ocular Surface Health With PF Tafluprost and Combined Therapy With PF Tafluprost and Dorzolamide/Timolol Fixed Combination in Open-angle Glaucoma Subjects Insufficiently Controlled With Latanoprost

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Dorzolamide/timolol (Primary) ; Tafluprost (Primary)
  • Indications Open-angle glaucoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2016 Primary endpoint (Mean 24-hour efficacy (average intraocular pressure readings over 24 hours)) has been met, according to results published in the Advances in Therapy journal.
    • 02 Dec 2016 Results of this study, published in the Advances in Therapy journal.
    • 24 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top